Portal de Periódicos da CAPES

How to Image Cardiac Amyloidosis

2019; Elsevier BV; Volume: 13; Issue: 6 Linguagem: Inglês

10.1016/j.jcmg.2019.07.015

1936-878X

Sharmila Dorbala, Sarah Cuddy, Rodney H. Falk,

Sarcoidosis and Beryllium Toxicity Research

Cardiac amyloidosis (CA) is one of the most rapidly progressive forms of heart disease, with a median survival from diagnosis, if untreated, ranging from <6 months for light chain amyloidosis to 3 to 5 years for transthyretin amyloidosis. Early diagnosis and accurate typing of CA are necessary for optimal management of these patients. Emerging novel disease modifying therapies increase the urgency to diagnose CA at an early stage and identify patients who may benefit from these life-saving therapies. The goal of this review is to provide a practical approach to echocardiography, cardiac magnetic resonance, and radionuclide imaging in patients with known or suspected CA.